Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

4 clinical studies listed.

Filters:

Prostate Cancer Screening

Tundra lists 4 Prostate Cancer Screening clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT06626022

Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.

The purpose of this study is to compare whether the FDA and Health Canada approved microUS is as effective as the currently used option (MRI) for imaging the prostate gland. Participants will be randomized into two groups to compare the imaging results of the current standard of care MRI and the new microUS. The study is looking to identify the most effective imaging modality to help guide whether you progress to have a prostate biopsy.

Gender: MALE

Ages: 50 Years - 70 Years

Updated: 2026-04-06

4 states

Prostate Cancer Screening
RECRUITING

NCT05608694

MRI Screening in Men at High Risk of Developing Prostate Cancer

The purpose of this study is to determine whether or not Magnetic Resonance Images (MRI) will identify high-grade cancers earlier and more frequently in men at high risk of developing prostate cancer.

Gender: MALE

Ages: 18 Years - Any

Updated: 2026-03-02

1 state

Prostate Cancer Screening
RECRUITING

NCT06923657

PSMA PET/MRI-Guided Prostate Biopsy for PI-RADS ≤3 and Prior Negative Biopsy

The goal is to provide more accurate diagnostic tools and optimized diagnostic workflows for clinically suspected prostate cancer patients with prior negative biopsies, improving early detection rates for csPCa and reducing missed diagnoses.

Gender: MALE

Ages: 30 Years - 85 Years

Updated: 2025-09-15

1 state

Prostate Cancer Screening
PSMA-PET
NOT YET RECRUITING

NCT06830265

Comparing Standard of Care Biopsy System to a Novel Biopsy Needle System by Computational Pathologic Analysis

Prostate biopsy is the definitive examination to establish the diagnosis of prostate cancer, but up to 40% of these biopsies overestimate or underestimate the severity of the disease. A novel biopsy needle system captures substantially more tissue than standard of care needles, but it is important to assess the retrieval of tissue for pathologic analyses. This study will compare quality and quantity of tissue retrieved by both systems. Further, tissue will be analyzed using computational pathology algorithms for atypical small acinar proliferation and Gleason scores in terms of tissue area, tissue length, and tissue tortuosity.

Gender: MALE

Ages: 18 Years - Any

Updated: 2025-02-17

Prostate Cancer Screening